<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452293</url>
  </required_header>
  <id_info>
    <org_study_id>EndoCore01</org_study_id>
    <nct_id>NCT03452293</nct_id>
  </id_info>
  <brief_title>SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients</brief_title>
  <acronym>SUPERSUBII</acronym>
  <official_title>SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoCore Lab s.r.l.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Italiana Vascolare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EndoCore Lab s.r.l.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de
      novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be
      performed based on a rigorous sample size calculation, which will allow us to have the
      statistical power to validate our conclusions and therefore establish the generalizability of
      this strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed as a prospective, open label, observational study.

      The study will collect information about the medical care patients receive during their
      planned procedure. No additional testing or procedures will be done.

      Patients elected for endovascular revascularization with SuperSub strategy will be asked
      their written consent to the use of their personal data.

      Revascularization will be performed as per standard procedure of the sites. After discharge
      all patients will attend clinic visits at 30 days (±14 days), 6 months (±30 days), 12 months
      (±30 days) and 24 months (±30 days). Angiographic follow-up will be performed only in
      symptomatic patients, as clinically indicated and with the aim for a new treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Primary Patency is defined as freedom from clinically driven TLR (CD-TLR) defined as repeat percutaneous intervention or surgical bypass graft to treat an angiographic significant restenosis (&gt;50%) at the level of the treated lesion ±10 mm (proximally and/or distally)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from Restenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from restenosis (diameter stenosis &gt; 50%, determined by peak systolic velocity ratio (PSVR) &gt;2.4 by duplex ultrasonography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Restenosis</measure>
    <time_frame>24 months</time_frame>
    <description>Freedom from restenosis (diameter stenosis &gt; 50%, determined by peak systolic velocity ratio (PSVR) &gt;2.4 by duplex ultrasonography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All Major Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Incidence of the composite of all Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of All Major Adverse Events</measure>
    <time_frame>24 Months</time_frame>
    <description>Incidence of the composite of all Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of Major Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent integrity assessment</measure>
    <time_frame>12 months</time_frame>
    <description>Stent integrity assessment will be evaluated with two oblique opposite projection X-ray images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent integrity assessment</measure>
    <time_frame>24 months</time_frame>
    <description>Stent integrity assessment will be evaluated with two oblique opposite projection X-ray images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Sustained Clinical Improvement</measure>
    <time_frame>6,12 and 24 months vs baseline</time_frame>
    <description>Clinical Improvement as assessed by Rutherford Class changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life improvement as assessed by EQ5D Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life improvement as assessed by SF12 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life improvement as assessed by EQ5D Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life improvement as assessed by SF12 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life improvement as assessed by EQ5D Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life improvement as assessed by SF12 Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Rates</measure>
    <time_frame>1 month</time_frame>
    <description>Major and Minor amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Rates</measure>
    <time_frame>6 months</time_frame>
    <description>Major and Minor amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Major and Minor amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation Rates</measure>
    <time_frame>24 months</time_frame>
    <description>Major and Minor amputations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost-efficiency analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Cost-efficiency analysis based on the comparison of the yearly procedural related costs and hospital stay(s) between patients treated with the SUPERSUB strategy, vs a propensity-matched historical cohort of patients with the same type of lesions (TASC C-D), treated by PTA alone, after subintimal crossing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-efficiency analysis</measure>
    <time_frame>24 months</time_frame>
    <description>Cost-efficiency analysis based on the comparison of the yearly procedural related costs and hospital stay(s) between patients treated with the SUPERSUB strategy, vs a propensity-matched historical cohort of patients with the same type of lesions (TASC C-D), treated by PTA alone, after subintimal crossing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical success</measure>
    <time_frame>1 month</time_frame>
    <description>Technical success defined as achievement of a final in-lesion residual diameter stenosis of ≤30% as determined by the angiographic core lab</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical success</measure>
    <time_frame>1 month</time_frame>
    <description>Clinical success defined as technical success without the occurrence of major adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success</measure>
    <time_frame>1 month</time_frame>
    <description>Procedural success defined as lesion success without the occurrence of major adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>ABI index or transcutaneous oxymetry (TcPO2) improvement</measure>
    <time_frame>6 and 12 months vs baseline</time_frame>
    <description>Improve in the ABI index or transcutaneous oxymetry (TcPO2)</description>
  </other_outcome>
  <enrollment type="Anticipated">92</enrollment>
  <condition>PAD</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent Peripheral System</intervention_name>
    <description>Peripheral PTA with Supera Stent implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by lower extremities artery disease and referred for the endovascular
        treatment of de novo or re-stenotic lesions (no in stent restenosis) in the
        femoro-popliteal arteries.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          -  Patients with CLI and TASC C-D Fem-Pop CTO's

          -  Age ≥18 years

          -  Patient has signed an approved consent form

          -  Patients without previous stenting of the Fem-Pop segment

        Angiographic Inclusion Criteria:

          -  Patent and hemodynamically normal iliac and common femoral arteries.

          -  At least one patent and healthy tibial vessel runoff to the foot.

          -  Patient has documented TASC C or D Fem-Pop CTO's prior to the study procedure

          -  Rutherford Category 4, 5 or 6

          -  Subintimal crossing of the occluded Fem-Pop vessels

          -  Supera Stenting From healthy to healthy arterial segment.

        Exclusion Criteria:

          -  Patient unwilling or unlikely to comply with Follow-Up schedule

          -  Endoluminal crossing of the CTO

          -  Inability to stent from &quot;healthy to healthy&quot; arterial segments.

          -  Inability to re-enter within the pre-specified Ideal Landing Zone (IDL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Salomone, MD</last_name>
    <role>Study Director</role>
    <affiliation>EndoCore Lab</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariano L Palena, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Casa di Cura Abano Terme</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry J Diaz, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Metro Health Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Salomone, MD</last_name>
    <phone>+39 3357378767</phone>
    <email>m.salomone@endocorelab.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariano L Palena, MD</last_name>
    <phone>+39 3498924343</phone>
    <email>marianopalena@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Larry J Diaz, Md,PhD</last_name>
      <phone>616-340-4730</phone>
      <email>ldiazjr71@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Avezzano</name>
      <address>
        <city>Avezzano</city>
        <state>AQ</state>
        <zip>67051</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Filauri, MD</last_name>
      <phone>+39 360913555</phone>
      <email>pfilauri@asl1abruzzo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica San Michele</name>
      <address>
        <city>Maddaloni</city>
        <state>CE</state>
        <zip>81024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Landino, MD</last_name>
      <phone>+39 3283414286</phone>
      <email>landinopietro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierfrancesco Veroux, MD,PhD</last_name>
      <phone>+39 3476601160</phone>
      <email>pveroux@unict.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo P Dionisi, MD</last_name>
      <phone>+39 3398515457</phone>
      <email>cpdionisi@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Abano Terme</name>
      <address>
        <city>Abano Terme</city>
        <state>Padova</state>
        <zip>35031</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano L Palena, MD</last_name>
      <phone>+39 3498924343</phone>
      <email>marianopalena@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Lenti, MD</last_name>
      <phone>+39 3356045805</phone>
      <email>massimo.lenti@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Gandini, MD,PhD</last_name>
      <phone>+39 3299213750</phone>
      <email>roberto.gandini@fastwebnet.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. San Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cesare Ambrogi, MD</last_name>
      <phone>+39 3382507288</phone>
      <email>cambrogivasc@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Sassari</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aldo Pischedda, MD,PhD</last_name>
      <phone>+39 079228330</phone>
      <email>apischedda@sirm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rovereto</name>
      <address>
        <city>Rovereto</city>
        <state>TN</state>
        <zip>38123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Bonvini, MD</last_name>
      <phone>+39 3479660371</phone>
      <email>stefano.bonvini@apss.tn.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Antonio Abate</name>
      <address>
        <city>Erice</city>
        <state>TP</state>
        <zip>91016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arian Frasheri, MD</last_name>
      <phone>+39 0923809177</phone>
      <email>adi.frasheri@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN Antonio Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Ruotolo, MD</last_name>
      <phone>+39 0817474133</phone>
      <email>carlo.ruotolo@aocardarelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

